Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome

Published:2023-05 Issue:5 Volume:81 Page:336-338
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Moroni Francesco¹,Ayers Michael P.¹,Dixon Dave L.²,Abbate Antonio¹

Affiliation:

1. Heart and Vascular Center, Division of Cardiology, and Berne Cardiovascular Research Center, School of Medicine, University of Virginia, Charlottesville, VA

2. Department of Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, VA

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference13 articles.

1. A review of PCSK9 inhibition, its effects beyond LDL receptors;Dixon;J Clin Lipidol.,2016

2. PCSK9 inhibitors: clinical evidence, implementation;Sabatine;Nat Rev Cardiol.,2019

3. Long-term evolocumab in patients with familial hypercholesterolemia;Santos;J Am Coll Cardiol.,2020

4. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia;Kastelein;Eur Heart J.,2015

5. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP